Edition:
United States

Aclaris Therapeutics Inc (ACRS.OQ)

ACRS.OQ on NASDAQ Stock Exchange Global Select Market

24.72USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$24.72
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
110,325
52-wk High
$33.21
52-wk Low
$21.35

Latest Key Developments (Source: Significant Developments)

Aclaris Therapeutics Receives FDA Approval For Eskata For Treatment Of Raised SKs
Friday, 15 Dec 2017 07:00am EST 

Dec 15 (Reuters) - Aclaris Therapeutics Inc ::ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS RECEIVES FDA APPROVAL FOR ESKATA™ (HYDROGEN PEROXIDE) TOPICAL SOLUTION, 40% (W/W) FOR THE TREATMENT OF RAISED SEBORRHEIC KERATOSES (SKS).ACLARIS THERAPEUTICS - FDA APPROVAL OF ESKATA BASED ON 2 PIVOTAL PHASE 3 TRIALS THAT SHOWED SAFETY & EFFICACY OF ESKATA FOR TREATMENT OF RAISED SKS.  Full Article

Aclaris Therapeutics says qtrly loss per share $0.63
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Aclaris Therapeutics Inc -:Aclaris Therapeutics reports third quarter 2017 financial results.Aclaris Therapeutics Inc - qtrly loss per share $0.63.Aclaris Therapeutics Inc - qtrly revenue of $684,000.Aclaris Therapeutics Inc- ‍cash burn for 2017 is now estimated to be in range of $56 million to $59 million​.Aclaris Therapeutics Inc- ‍research and development expenses for 2017 are now estimated to be in range of $39 million to $42 million​.  Full Article

Aclaris Therapeutics announces publication of phase 2 trial data of A-101 for treatment of facial seborrheic keratosis
Tuesday, 19 Sep 2017 08:00am EDT 

Sept 19 (Reuters) - Aclaris Therapeutics Inc :Aclaris Therapeutics announces publication of data from phase 2 clinical trial of A-101 topical solution for treatment of facial seborrheic keratosis.Aclaris Therapeutics Inc - ‍ in trial, A-101 achieved statistical significance in clearing SK lesions on face in a dose-related fashion​.Aclaris Therapeutics Inc - ‍ FDA's Prescription Drug User Fee Act Action date for new drug application is December 24, 2017​.Aclaris Therapeutics Inc - ‍ A-101 was well tolerated at both concentrations studied​.Aclaris Therapeutics Inc - ‍there were no treatment-related adverse events among patients treated with A-101​.  Full Article

Vivo Ventures VII LLC reports 9.5 pct stake in Aclaris Therapeutics
Monday, 14 Aug 2017 05:29pm EDT 

Aug 14 (Reuters) - Aclaris Therapeutics Inc :Vivo Ventures VII LLC reports 9.5 percent stake in Aclaris Therapeutics Inc as of March 15, 2017 - SEC filing.Vivo Ventures VII LLC had previously reported 13.34 percent in Aclaris Therapeutics Inc as of February 28, 2017.  Full Article

Aclaris announces pricing of public offering of common stock
Thursday, 10 Aug 2017 09:23pm EDT 

Aug 10 (Reuters) - Aclaris Therapeutics Inc -:Aclaris announces pricing of public offering of common stock.Announces public offering of 3.26 million units at a public offering price of $23.02 per common unit.  Full Article

Aclaris announces proposed public offering of common stock
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Aclaris Therapeutics Inc -:Aclaris announces proposed public offering of common stock.Aclaris Therapeutics Inc says that it intends to offer and sell $75 million of shares of its common stock in an underwritten public offering.  Full Article

Aclaris Therapeutics posts Q2 loss per share $‍0.56​
Tuesday, 8 Aug 2017 07:01am EDT 

Aug 8 (Reuters) - Aclaris Therapeutics Inc :Aclaris Therapeutics reports second quarter 2017 financial results.Qtrly loss per share $‍0.56​.‍reiterates 2017 financial guidance for net cash burn, total operating expenses, research and development expenses​.Aclaris Therapeutics - ‍sees its cash, cash equivalents, marketable securities as of June 30 sufficient to fund operations through at least end of 2018​.  Full Article

Aclaris Therapeutics acquires Confluence Life Sciences
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Aclaris Therapeutics Inc :Aclaris Therapeutics acquires Confluence Life Sciences, Inc..Aclaris Therapeutics Inc - at closing, aclaris paid approximately $10 million in cash.Aclaris Therapeutics says also issued about 350,000 shares of its common stock of about $10 million on closing date, to former equityholders of confluence​.Aclaris Therapeutics - confluence equity holders eligible to receive up to additional $80 million in contingent payments upon achievement of certain milestones.  Full Article

Aclaris Therapeutics has submitted a marketing authorization application with medicines product agency in Sweden
Thursday, 3 Aug 2017 08:00am EDT 

Aug 3 (Reuters) - Aclaris Therapeutics Inc :Has submitted a marketing authorization application with medicines product agency in Sweden.Aclaris Therapeutics - marketing authorization application is for its product candidate A-101 40% topical solution for treatment of seborrheic keratosis.  Full Article

Aclaris Therapeutics submits investigational new drug application for ATI-50002
Wednesday, 2 Aug 2017 08:00am EDT 

Aug 2 (Reuters) - Aclaris Therapeutics Inc ::Aclaris Therapeutics submits investigational new drug application for ATI-50002 to treat Alopecia Areata.Aclaris therapeutics inc - ‍trials will be conducted at multiple investigational centers across united states​.Aclaris therapeutics inc - ‍Aclaris expects to initiate two phase 2 clinical trials of ATI-50002 in second half of 2017​.  Full Article

Aclaris's drug to treat common skin growth gets FDA nod

Aclaris Therapeutics Inc's drug to treat a common kind of skin growth called seborrheic keratoses received approval from the U.S. Food and Drug Administration, the company said on Friday.